Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRAEA: Pembrolizumab, Radiotherapy, and Axatilimab in Metastatic TNBC
NCT07015853Phase 2Not yet recruiting
- Sponsor
- Stephen Shiao
- Start
- Jun 2026
- Primary completion
- Jul 2033
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axatilimab in triple-negative breast cancer (TNBC), sponsored by Stephen Shiao. Primary endpoint: Overall Response Rate up to 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
axatilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07015853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015853.